Terumo Blood and Cell Technologies: CAR-T Expansion Data and Pre-/Post-Thaw Analysis
Thursday, May 30, 2024 12:45 PM - 01:45 PM
Room 211
Corporate Session
Speaker
A detailed investigation into the expansion of genetically modified chimeric antigen receptor (CAR) T cells on the Quantum Flex Cell Expansion System was recently completed as part of the strategic collaboration between BioCentriq and Terumo Blood and Cell Technologies. This presentation not only details the technical results of this study, but also the rapid technology transfer of an end-to-end manufacturing protocol to a contracted site.
Session Objectives
- David Smith, Vice President of Development, Biocentriq, United States
A detailed investigation into the expansion of genetically modified chimeric antigen receptor (CAR) T cells on the Quantum Flex Cell Expansion System was recently completed as part of the strategic collaboration between BioCentriq and Terumo Blood and Cell Technologies. This presentation not only details the technical results of this study, but also the rapid technology transfer of an end-to-end manufacturing protocol to a contracted site.
Session Objectives
- The seamless technology transfer process and operator training
- The high dynamic range of Quantum Flex, capable of supporting starting cell numbers between 1-15M up to 2.6B in 7 days*
- Cell expansion kinetics, phenotypic analysis, and functional assays at critical process steps
SPONSORED BY:
